183 related articles for article (PubMed ID: 35312698)
1. A three-dimensional immune-oncology model for studying in vitro primary human NK cell cytotoxic activity.
Thongsin N; Wattanapanitch M
PLoS One; 2022; 17(3):e0264366. PubMed ID: 35312698
[TBL] [Abstract][Full Text] [Related]
2. Reversing Hypoxia with PLGA-Encapsulated Manganese Dioxide Nanoparticles Improves Natural Killer Cell Response to Tumor Spheroids.
Murphy DA; Cheng H; Yang T; Yan X; Adjei IM
Mol Pharm; 2021 Aug; 18(8):2935-2946. PubMed ID: 34191525
[TBL] [Abstract][Full Text] [Related]
3. A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids.
Schwietzer YA; Susek KH; Chen Z; Alici E; Wagner AK
Methods Cell Biol; 2023; 178():43-61. PubMed ID: 37516528
[TBL] [Abstract][Full Text] [Related]
4. A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity.
Sherman H; Gitschier HJ; Rossi AE
Front Immunol; 2018; 9():857. PubMed ID: 29740450
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.
Giannattasio A; Weil S; Kloess S; Ansari N; Stelzer EH; Cerwenka A; Steinle A; Koehl U; Koch J
BMC Cancer; 2015 May; 15():351. PubMed ID: 25933805
[TBL] [Abstract][Full Text] [Related]
6. Physical Characterization of Colorectal Cancer Spheroids and Evaluation of NK Cell Infiltration Through a Flow-Based Analysis.
Sargenti A; Musmeci F; Bacchi F; Delprete C; Cristaldi DA; Cannas F; Bonetti S; Pasqua S; Gazzola D; Costa D; Villa F; Zocchi MR; Poggi A
Front Immunol; 2020; 11():564887. PubMed ID: 33424829
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
[TBL] [Abstract][Full Text] [Related]
8. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment.
Courau T; Bonnereau J; Chicoteau J; Bottois H; Remark R; Assante Miranda L; Toubert A; Blery M; Aparicio T; Allez M; Le Bourhis L
J Immunother Cancer; 2019 Mar; 7(1):74. PubMed ID: 30871626
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
10. Facile discovery of a therapeutic agent for NK-mediated synergistic antitumor effects using a patient-derived 3D platform.
Lee YE; Yuk CM; Lee M; Han KC; Jun E; Kim TS; Ku JL; Im SG; Lee E; Jang M
Biomater Sci; 2022 Feb; 10(3):678-691. PubMed ID: 34940764
[TBL] [Abstract][Full Text] [Related]
11. Kinetic, imaging based assay to measure NK cell cytotoxicity against adherent cells.
Croom-Perez TJ; Robles-Carillo LD; Oyer JL; Dieffenthaller TA; Hasan MF; Copik AJ
Methods Cell Biol; 2023; 178():63-91. PubMed ID: 37516529
[TBL] [Abstract][Full Text] [Related]
12. Generation of Tumor Spheroids to Evaluate T Cell and NK Cell Cytotoxicity.
Poggi A
Curr Protoc; 2022 Feb; 2(2):e366. PubMed ID: 35170872
[TBL] [Abstract][Full Text] [Related]
13. An Immunocompetent Microphysiological System to Simultaneously Investigate Effects of Anti-Tumor Natural Killer Cells on Tumor and Cardiac Microtissues.
Nguyen OTP; Misun PM; Lohasz C; Lee J; Wang W; Schroeder T; Hierlemann A
Front Immunol; 2021; 12():781337. PubMed ID: 34925361
[TBL] [Abstract][Full Text] [Related]
14. Heterotypic tumor spheroids: a platform for nanomedicine evaluation.
Vakhshiteh F; Bagheri Z; Soleimani M; Ahvaraki A; Pournemat P; Alavi SE; Madjd Z
J Nanobiotechnology; 2023 Aug; 21(1):249. PubMed ID: 37533100
[TBL] [Abstract][Full Text] [Related]
15. High-Throughput 3D
Song J; Choi H; Koh SK; Park D; Yu J; Kang H; Kim Y; Cho D; Jeon NL
Front Immunol; 2021; 12():733317. PubMed ID: 34630415
[TBL] [Abstract][Full Text] [Related]
16. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
17. Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells.
Vahedi F; Nham T; Poznanski SM; Chew MV; Shenouda MM; Lee D; Ashkar AA
Sci Rep; 2017 Sep; 7(1):12083. PubMed ID: 28935883
[TBL] [Abstract][Full Text] [Related]
18.
Carannante V; Wiklund M; Önfelt B
Front Immunol; 2023; 14():1135148. PubMed ID: 37457703
[TBL] [Abstract][Full Text] [Related]
19. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
20. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
